Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (37)
Sudha Raghunath, Emma K Guymer, Yifat Glikmann-Johnston, Vera Golder, Rangi Kandane Rathnayake, Eric F Morand, Julie C Stout & Alberta Hoi. (2023) Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology 62:1, pages 190-199.
Crossref
Crossref
Thomas Morel, Stefan Cano, Susan J Bartlett, Caroline Gordon, Birgit Haier, Antoine Regnault, Matthias Schneider, Christian Stach & Sophie Cleanthous. (2022) The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus. Rheumatology 61:8, pages 3329-3340.
Crossref
Crossref
Rebecca Williams-Hall, Pamela Berry, Nicola Williamson, Melissa Barclay, Anna Roberts, Adam Gater, Chloe Tolley, Helena Bradley, Amy Ward, Elizabeth Hsia, Qing Zuraw, Patricia DeLong, Zahi Touma & Vibeke Strand. (2022) Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN). Lupus Science & Medicine 9:1, pages e000712.
Crossref
Crossref
Sophie Cleanthous, Sara Strzok, Birgit Haier, Stefan Cano & Thomas Morel. (2021) The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model. Rheumatology and Therapy 9:1, pages 95-108.
Crossref
Crossref
Fandresena Arilala Sendrasoa, Tsiory Iarintsoa Razafimaharo, Léophonte Ramily, Mendrika Fifaliana Rakotoarisaona, Malalaniaina Andrianarison, Onivola Raharolahy, Volatantely Tobiniaina Ratovonjanahary, Naina Harinjara Razanakoto, Irina Mamisoa Ranaivo, Lala Soavina Ramarozatovo & Fahafahantsoa Rapelanoro Rabenja. (2021) Quality of life in lupus erythematosus female patients with cutaneous lesions in Antananarivo, Madagascar. International Journal of Women's Dermatology 7:5, pages 743-746.
Crossref
Crossref
Sophie Cleanthous, Sabine Bongardt, Patrick Marquis, Christian Stach, Stefan Cano & Thomas Morel. (2021) Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies. Rheumatology and Therapy 8:3, pages 1287-1301.
Crossref
Crossref
Zahi Touma, Dafna D. Gladman, Moe Zandy, Jiandong Su, Nicole Anderson & Murray B. Urowitz. (2021) Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. Arthritis Care & Research 73:9, pages 1243-1249.
Crossref
Crossref
Lily McMorrow, Jerik Leung, Vibeke Strand & Alfred H. J. Kim. 2021. Outcome Measures and Metrics in Systemic Lupus Erythematosus. Outcome Measures and Metrics in Systemic Lupus Erythematosus
213
227
.
Vera Golder & Michel W P Tsang-A-Sjoe. (2020) Treatment targets in SLE: remission and low disease activity state. Rheumatology 59:Supplement_5, pages v19-v28.
Crossref
Crossref
Nanda Gamad, Ashish Kumar Kakkar & Smita Pattanaik. (2020) Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials. Lupus 29:8, pages 1002-1003.
Crossref
Crossref
Alexandra Legge, Susan Kirkland, Kenneth Rockwood, Pantelis Andreou, Sang‐Cheol Bae, Caroline Gordon, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Daniel J. Wallace, Sasha Bernatsky, Ann E. Clarke, Joan T. Merrill, Ellen M. Ginzler, Paul R. Fortin, Dafna D. Gladman, Murray B. Urowitz, Ian N. Bruce, David A. Isenberg, Anisur Rahman, Graciela S. Alarcón, Michelle Petri, Munther A. Khamashta, M. A. Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Asad A. Zoma, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Ronald F. Vollenhoven, Andreas Jonsen, Ola Nived, Manuel Ramos‐Casals, Diane L. Kamen, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Anca Askanase & John G. Hanly. (2020) Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis & Rheumatology 72:4, pages 658-666.
Crossref
Crossref
Alexandra Legge, Susan Kirkland, Kenneth Rockwood, Pantelis Andreou, Sang‐Cheol Bae, Caroline Gordon, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Daniel J. Wallace, Sasha Bernatsky, Ann E. Clarke, Joan T. Merrill, Ellen M. Ginzler, Paul Fortin, Dafna D. Gladman, Murray B. Urowitz, Ian N. Bruce, David A. Isenberg, Anisur Rahman, Graciela S. Alarcón, Michelle Petri, Munther A. Khamashta, M. A. Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Kristjan Steinsson, Asad A. Zoma, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Ronald F. Vollenhoven, Andreas Jonsen, Ola Nived, Manuel Ramos‐Casals, Diane L. Kamen, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Anca Askanase & John G. Hanly. (2019) Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology 71:8, pages 1297-1307.
Crossref
Crossref
Ioannis Parodis, Angie H. Lopez Benavides, Agneta Zickert, Susanne Pettersson, Sonia Möller, Elisabet Welin Henriksson, Anne Voss & Iva Gunnarsson. (2019) The Impact of Belimumab and Rituximab on Health‐Related Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care & Research 71:6, pages 811-821.
Crossref
Crossref
Alfred H. J. Kim, Vibeke Strand, Deepali P. Sen, Qiang Fu, Nancy L. Mathis, Martin J. Schmidt, Robin R. Bruchas, Nick R. Staten, Paul K. Olson, Chad M. Stiening & John P. Atkinson. (2019)
Association of Blood Concentrations of Complement Split Product
iC
3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity
. Arthritis & Rheumatology 71:3, pages 420-430.
Crossref
Crossref
Champa Nataraja & Eric Morand. 2019. Dubois' Lupus Erythematosus and Related Syndromes. Dubois' Lupus Erythematosus and Related Syndromes
661
672
.
Zhi-Wei Lai, Ryan Kelly, Thomas Winans, Ivan Marchena, Ashwini Shadakshari, Julie Yu, Maha Dawood, Ricardo Garcia, Hajra Tily, Lisa Francis, Stephen V Faraone, Paul E Phillips & Andras Perl. (2018) Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. The Lancet 391:10126, pages 1186-1196.
Crossref
Crossref
Andrew Kwan, Vibeke Strand & Zahi Touma. (2017) The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. Current Treatment Options in Rheumatology 3:4, pages 308-321.
Crossref
Crossref
Diane Apostolopoulos & Eric F. Morand. (2016) It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology, pages kew406.
Crossref
Crossref
Sophie Cleanthous, David Alan Isenberg, Stanton Peter Newman & Stefan John Cano. (2016) Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study. Health and Quality of Life Outcomes 14:1.
Crossref
Crossref
M A Machado Escobar, M S Yacuzzi, R N Martinez, L González Lucero, V I Bellomio, M Santana, L Galindo, M M Mayer, J C Barreira, J Sarano, G Gomez, M V Collado, A Martinez, M C Orozco, G Betancur, F Dal Pra, A Sanchez, V Juarez & E V Lucero. (2016) Validation of an Argentine version of Lupus Quality of Life questionnaire. Lupus 25:14, pages 1615-1622.
Crossref
Crossref
M A Mahieu, V Strand, L S Simon, P E Lipsky & R Ramsey-Goldman. (2016) A critical review of clinical trials in systemic lupus erythematosus. Lupus 25:10, pages 1122-1140.
Crossref
Crossref
Brian Bekker Hansen & Lise Højbjerre. 2016. Patient Reported Outcome Measures in Rheumatic Diseases. Patient Reported Outcome Measures in Rheumatic Diseases
149
173
.
W. P. Kennedy, R. Maciuca, K. Wolslegel, W. Tew, A. R. Abbas, C. Chaivorapol, A. Morimoto, J. M. McBride, P. Brunetta, B. C. Richardson, J. C. Davis, T. W. Behrens & M. J. Townsend. (2015) Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Science & Medicine 2:1, pages e000080-e000080.
Crossref
Crossref
Yan Zhang, Celia P. Corona-Villalobos, Adnan N. Kiani, John Eng, Ihab R. Kamel, Stefan L. Zimmerman & Michelle Petri. (2014) Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. The International Journal of Cardiovascular Imaging 31:2, pages 389-397.
Crossref
Crossref
Vibeke Strand & Alvina D. Chu. 2015. Rheumatology. Rheumatology
1093
1098
.
Laura Holloway, Louise Humphrey, Louise Heron, Claire Pilling, Helen Kitchen, Lise Højbjerre, Martin Strandberg-Larsen & Brian Bekker Hansen. (2014) Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health and Quality of Life Outcomes 12:1.
Crossref
Crossref
Vijay Rao & Caroline Gordon. (2014) Advances in the assessment of lupus disease activity and damage. Current Opinion in Rheumatology 26:5, pages 510-519.
Crossref
Crossref
Arif Kaya, Berna Goker, Elife Senem Cura, Mehmet Engin Tezcan, Abdurrahman Tufan, Rıdvan Mercan, Berivan Bitik, Seminur Haznedaroglu, Mehmet Akif Ozturk, Rachel A. Mikolaitis-Preuss, Joel A. Block & Meenakshi Jolly. (2013) Turkish lupusPRO: cross-cultural validation study for lupus. Clinical Rheumatology 33:8, pages 1079-1084.
Crossref
Crossref
Richard Furie, Michelle A Petri, Vibeke Strand, Dafna D Gladman, Z John Zhong & William W Freimuth. (2014) Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Science & Medicine 1:1, pages e000031.
Crossref
Crossref
Vibeke Strand, Roger A Levy, Ricard Cervera, Michelle A Petri, Helen Birch, William W Freimuth, Z John Zhong & Ann E Clarke. (2014) Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Annals of the Rheumatic Diseases 73:5, pages 838-844.
Crossref
Crossref
V. Strand, M. Petri, K. Kalunian, C. Gordon, D. J. Wallace, K. Hobbs, L. Kelley, B. Kilgallen, W. A. Wegener & D. M. Goldenberg. (2013) Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology 53:3, pages 502-511.
Crossref
Crossref
Daniel J Wallace, Kenneth Kalunian, Michelle A Petri, Vibeke Strand, Frederic A Houssiau, Marilyn Pike, Brian Kilgallen, Sabine Bongardt, Anna Barry, Lexy Kelley & Caroline Gordon. (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Annals of the Rheumatic Diseases 73:1, pages 183-190.
Crossref
Crossref
Michelle Petri, Ariane K. Kawata, Ancilla W. Fernandes, Kavita Gajria, Warren Greth, Asha Hareendran & Dominique Ethgen. (2013) Impaired Health Status and the Effect of Pain and Fatigue on Functioning in Clinical Trial Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology 40:11, pages 1865-1874.
Crossref
Crossref
V Strand, C Galateanu, DS Pushparajah, E Nikaï, J Sayers, R Wood & RF van Vollenhoven. (2013) Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey. Lupus 22:8, pages 819-826.
Crossref
Crossref
Daniel J. Wallace, Caroline Gordon, Vibeke Strand, Kathryn Hobbs, Michelle Petri, Kenneth Kalunian, Frederic Houssiau, Paul P. Tak, David A. Isenberg, Lexy Kelley, Brian Kilgallen, Anna N. Barry, William A. Wegener & David M. Goldenberg. (2013) Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 52:7, pages 1313-1322.
Crossref
Crossref
Anna Nuttall & David A. Isenberg. (2013) Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: New aspects. Best Practice & Research Clinical Rheumatology 27:3, pages 309-318.
Crossref
Crossref
M García-Carrasco, C Mendoza-Pinto, MH Cardiel, S Méndez-Martínez, A García-Villaseñor, C Jiménez-Hernández, NE Alonso-García, R Briones-Rojas, G Ramos-Álvarez & A López-Colombo. (2012) Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL©. Lupus 21:11, pages 1219-1224.
Crossref
Crossref